Browsing Tag
LAG-3
1 post
Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer
Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment…